Merck said on Monday it will split its human-health business into two divisions, separating its blockbuster cancer franchise led by Keytruda from its non-oncology medicines.
The shake-up comes as the drugmaker braces for the looming loss of exclusivity on Keytruda, which accounted for nearly half of Merck’s total revenue in 2025. Shares of the U.S. drugmaker were up 1.4% in premarket trading.
Sign up here.
The news was f… [430 chars]
Source: Reuters | Published: 2026-02-23T11:22:57Z
Credit: Reuters
